AMYLYX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.83 USD | 0.00% |
|
+4.27% | -87.57% |
| May. 14 | Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating | MT |
| May. 09 | Transcript : Amylyx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 2,448 | 993.9 | 124.5 | - | - |
| Enterprise Value (EV) 1 | 2,101 | 622.5 | 37.07 | 61.95 | -9.676 |
| P/E ratio | -10.9 x | 21 x | -0.61 x | -1.39 x | -1.76 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 110 x | 2.61 x | 1.28 x | - | 965 x |
| EV / Revenue | 94.5 x | 1.63 x | 0.38 x | - | -75 x |
| EV / EBITDA | -10.5 x | 15.6 x | -0.13 x | -0.5 x | 0.08 x |
| EV / FCF | -11.5 x | 58.3 x | 0.33 x | 0.36 x | -0.04 x |
| FCF Yield | -8.68% | 1.72% | 302% | 281% | -2,412% |
| Price to Book | - | 2.26 x | - | - | - |
| Nbr of stocks (in thousands) | 66,256 | 67,518 | 68,006 | - | - |
| Reference price 2 | 36.95 | 14.72 | 1.830 | 1.830 | 1.830 |
| Announcement Date | 3/13/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.285 | 22.23 | 380.8 | 97.16 | - | 0.129 |
| EBITDA 1 | - | - | -200.9 | 39.89 | -296 | -123.6 | -128.7 |
| EBIT 1 | - | -82.69 | -201.3 | 38.8 | -259.2 | -125.6 | -108.2 |
| Operating Margin | - | -29,013.33% | -905.72% | 10.19% | -266.81% | - | -83,861.05% |
| Earnings before Tax (EBT) 1 | - | -87.93 | - | 54.3 | -289.3 | -126.8 | -89.7 |
| Net income 1 | -42.28 | -87.93 | -198.4 | 49.27 | -205.9 | -93.19 | -79 |
| Net margin | - | -30,852.98% | -892.38% | 12.94% | -211.95% | - | -61,240.89% |
| EPS 2 | -6.960 | -13.35 | -3.390 | 0.7000 | -3.018 | -1.318 | -1.038 |
| Free Cash Flow 1 | - | -75.15 | -182.4 | 10.68 | 111.8 | 174 | 233.4 |
| FCF margin | - | -26,369.12% | -820.5% | 2.8% | 115.07% | - | 180,930.23% |
| FCF Conversion (EBITDA) | - | - | - | 26.77% | - | - | - |
| FCF Conversion (Net income) | - | - | - | 21.67% | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 4/26/21 | 3/30/22 | 3/13/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 0.345 | 21.88 | 71.43 | 98.22 | 102.7 | 108.4 | 88.64 | 8.53 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -52.28 | -47.81 | -54.25 | -54.68 | -44.59 | -2.053 | 20.2 | 18.72 | 1.934 | -11.67 | -67.04 | -53.67 | -43.99 | -35.35 |
| Operating Margin | - | - | - | -15,849.57% | -203.76% | -2.87% | 20.57% | 18.23% | 1.78% | -13.16% | -785.87% | - | - | - |
| Earnings before Tax (EBT) 1 | -54.24 | -47.7 | - | - | - | 1.403 | 24.01 | 22.41 | 6.476 | -118.6 | -74.42 | -55.09 | -41.25 | - |
| Net income 1 | -54.24 | -47.85 | -54.07 | -53.76 | -42.7 | 1.573 | 22.07 | 20.89 | 4.731 | -118.8 | -47.51 | -37.57 | -29.64 | - |
| Net margin | - | - | - | -15,581.45% | -195.13% | 2.2% | 22.47% | 20.35% | 4.36% | -134.01% | -557.02% | - | - | - |
| EPS 2 | -4.150 | -0.9300 | -0.9300 | -0.9200 | -0.6500 | 0.0200 | 0.3100 | 0.3000 | 0.0700 | -1.750 | -0.6975 | -0.5500 | -0.4350 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/13/23 | 5/11/23 | 8/10/23 | 11/9/23 | 2/22/24 | 5/9/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 96.1 | 347 | 371 | 87.4 | 62.5 | 134 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -75.2 | -182 | 10.7 | 112 | 174 | 233 |
| ROE (net income / shareholders' equity) | - | - | -209% | 12.7% | -26% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | 10.8% | - | - | - |
| Assets 1 | - | - | - | 454.5 | - | - | - |
| Book Value Per Share | - | - | - | 6.520 | - | - | - |
| Cash Flow per Share 2 | - | - | -3.070 | 0.1700 | -0.5500 | -1.690 | - |
| Capex 1 | - | 0.35 | 2.53 | 1.24 | 1.3 | 2.9 | 3.34 |
| Capex / Sales | - | 123.86% | 11.36% | 0.33% | 1.33% | - | 2,586.82% |
| Announcement Date | 4/26/21 | 3/30/22 | 3/13/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
1.83
USD
Average target price
4.083
USD
Spread / Average Target
+123.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -87.57% | 124M | |
| -2.32% | 92.59B | |
| +3.68% | 41.43B | |
| -10.90% | 33.49B | |
| -19.56% | 14.62B | |
| -9.06% | 12.77B | |
| -11.34% | 11.58B | |
| -43.53% | 11.35B | |
| +3.75% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- AMLX Stock
- Financials Amylyx Pharmaceuticals, Inc.
